Background:

Evidence suggests that inflammation increases risk for ovarian cancer. Aspirin has been shown to decrease ovarian cancer risk, though the mechanism is unknown. Studies of inflammatory markers, lipid molecules such as arachidonic acid, linoleic acid, and alpha-linoleic acid metabolites, and development of ovarian cancer are essential to understand the potential mechanisms.

Methods:

We conducted a nested case–control study (157 cases/156 matched controls) within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Unconditional logistic regression was used to estimate the association between prediagnostic serum levels of 31 arachidonic acid/linoleic acid/alpha-linoleic acid metabolites and risk of ovarian cancer.

Results:

Five of the 31 arachidonic acid/linoleic acid/alpha-linoleic acid (free fatty acids) metabolites were positively associated with ovarian cancer risk: 8-HETE [tertile 3 vs. 1: OR 2.53 (95% confidence interval [CI] 1.18–5.39), Ptrend 0.02], 12,13-DHOME [2.49 (1.29–4.81), 0.01], 13-HODE [2.47 (1.32–4.60), 0.005], 9-HODE [1.97 (1.06–3.68), 0.03], 9,12,13-THOME [2.25 (1.20–4.21), 0.01]. In analyses by subtype, heterogeneity was suggested for 8-HETE [serous OR (95% CI): 2.53 (1.18–5.39) vs. nonserous OR (95% CI): 1.15 (0.56–2.36), Phet 0.1] and 12,13-EpOME [1.95 (0.90–4.22) vs. 0.82 (0.39–1.73), 0.05].

Conclusions:

Women with increased levels of five fatty acid metabolites (8-HETE, 12,13-DHOME, 13-HODE, 9-HODE, and 9,12,13-THOME) were at increased risk of developing ovarian cancer in the ensuing decade. All five metabolites are derived from either arachidonic acid (8-HETE) or linoleic acid (12,13-DHOME, 13-HODE, 9-HODE, 9,12,13-THOME) via metabolism through the LOX/cytochrome P450 pathway.

Impact:

The identification of these risk-related fatty acid metabolites provides mechanistic insights into the etiology of ovarian cancer and indicates the direction for future research.

This article is featured in Highlights of This Issue, p. 1

Inflammation is thought to play a role in the development and progression of ovarian cancer. Usually inflammation is beneficial such that it activates the immune process and protects the body from infections and diseases, but chronic inflammation induces prolonged exposure of the cells to the mediators of inflammation (1, 2). These mediators can then promote tumorigenesis. Inflammation during ovulation or inflammatory chronic disease that affects the fallopian tubes and/or ovary (e.g., endometriosis and pelvic inflammatory disease) is associated with increased risk of ovarian cancer (3–5). The use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, is associated with reductions in risk (6). Although a specific mechanism is yet to be determined, reduced risk of ovarian cancer due to aspirin might be due to the medication's anti-inflammatory effect. Aspirin and other NSAIDs block the synthesis of proinflammatory prostaglandin synthesis by inhibiting the COX enzyme (7).

In addition to prostaglandin synthesis, the inflammatory response involves biologically active lipid molecules, arachidonic acid, and an essential fatty acid linoleic acid and its metabolites (Fig. 1; refs. 8–10). Essential fatty acids mainly comprise two groups: omega-6 fatty acids (linoleic acid) and omega-3 fatty acids (alpha-linoleic acid). Omega-6 fatty acids are converted to arachidonic acid, and omega-3 fatty acids are converted to docosahexaenoic acid and eventually to arachidonic acid (11, 12). In addition to essential fatty acid metabolism to arachidonic acid, arachidonic acid is also released from the phospholipids of the cell membrane during inflammation in response to various stimuli like cytokines, hormones, and stress (7). Arachidonic acid is acted upon by three enzymes: COX, lipoxygenase (LOX), and cytochrome P450. The COX activity on arachidonic acid produces PGG2 and PGH2, which is later converted to prostanoids including prostaglandins (PGD2, PGE2, and PGF2a), prostacyclins (PG12), and thromboxanes (TXA2 and TXB2). COX exists in two isoforms, COX-1 and COX-2. Three forms of LOXs (5-LOX, 12-LOX, and 15-LOX) acts on arachidonic acid to produce hydroxyperoxyeicosatetraenoic acids (HPETE), HETEs, and leukotrienes (LT). The enzyme cytochrome P450 produces HETEs and epoxides. Free fatty acid (arachidonic acid/linoleic acid/alpha-linoleic acid) metabolites are implicated in various signaling pathways involved in physiologic processes such as cell differentiation, cell migration, platelet aggregation, angiogenesis, and regulation of immune functions (8, 13), and thus may play a role in cancer initiation and/or promotion.

Figure 1.

Essential fatty acid metabolism pathway. The current assay measured the 31 arachidonic acid/linoleic acid/alpha-linoleic acid metabolites in the shaded boxes. The metabolites in the outlined boxes were not measured using the current assay. *, 20-HETE and 19-HETE metabolites undetectable in nearly all samples. **, 5,6-EET was excluded from analyses given its known limitations in its detection via LC/MS-MS.

Figure 1.

Essential fatty acid metabolism pathway. The current assay measured the 31 arachidonic acid/linoleic acid/alpha-linoleic acid metabolites in the shaded boxes. The metabolites in the outlined boxes were not measured using the current assay. *, 20-HETE and 19-HETE metabolites undetectable in nearly all samples. **, 5,6-EET was excluded from analyses given its known limitations in its detection via LC/MS-MS.

Close modal

Because of a potentially tumorigenic role of arachidonic acid, the inhibitors of arachidonic acid metabolites have been widely studied for their potential role in cancer treatment but the precise molecular mechanism by which these metabolites drive tumorigenesis is unknown (14). Epidemiologic studies investigating the role of free fatty acid metabolites in ovarian cancer are limited. To understand the role of arachidonic acid and linoleic acid pathway-induced inflammation in the etiology of ovarian cancer, we assessed several free fatty acid metabolites in a nested case–control study within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. As ovarian cancer subtypes are known to have a heterogeneous etiology, we further evaluated associations by serous/nonserous subtype and time between blood draw and cancer diagnosis.

Study design

We conducted a nested case–control study within the screening arm of the PLCO Cancer Screening Trial, a randomized two-arm screening trial of men and women, ranging in age 55 to 74 years was conducted between 1993 and 2001 (15). Briefly, 78,216 women recruited from 10 centers across the United States (Birmingham, AL; Denver, CO; Detroit, MI; Honolulu, HI; Marshfield, WI; Minneapolis, MN; Pittsburgh, PA; Salt Lake City, UT; St. Louis, MO; and Washington, DC). Participants in the screening arm provided a blood sample at baseline and during five follow-up medical examinations and were stored at −70°C (16). All participants completed a self-administered baseline questionnaire. Cancer cases were identified by annual mailed questionnaires which were then confirmed by linking to population-based registries and the National Death Index. Medical and pathologic records were obtained when possible.

To avoid the possibility of reverse causality, cases for our study were 157 individuals diagnosed between 2 and 14 years after blood collection with follow-up through December 2010. To ensure a relatively equal distribution of specimens between 2 and 14 years prior to diagnosis, 10.9% of samples selected were measured at baseline and the remaining at follow-up visits (16.3% year 1, 25.9% year 2, 13.7% year 3, and 33.2% year 4). For inclusion in our study, serum samples were selected from a prediagnostic blood draw given the availability of unthawed serum, consent to biochemical studies, completion of the baseline questionnaire, and no history of cancer (except nonmelanoma skin cancer). There were 160 cases identified out of which three were excluded from the study because the sample volume was not sufficient. Controls were women with no history of oophorectomy at the time of diagnosis of their matched case and were matched on age at blood collection (55–59, 60–64, 65–69, 70+ years), race (white, black, other), study center, and time (a.m. and p.m.) and date (3-month categories) of blood collection. Serum specimens from a single visit were measured for each study subject. All the study participants provided written informed consent and the study received approval from the institutional review board of the involved study centers and from the National Cancer Institute.

Laboratory analysis

Levels of 34 free fatty acid metabolites generated through three different pathways—COX pathway, cytochrome P450 pathway, and LOX pathway—were measured in serum. All free fatty acid metabolites were separated by electrospray ionization LC (Agilent 1200 series capillary HPLC) and quantified using tandem mass spectrometry (MS/MS, MDS Sciex API 3000, negative ion mode) with a Turbolon Spray and scheduled multiple reaction. The details of the assay have been published previously (17–19). Concentrations (pg/mL) were quantified with Analyst software (v 1.5; Applied Biosystem) using metabolite and internal standard peaks for each sample.

To evaluate assay performance, we included duplicate quality control (QC) samples in each batch and calculated the within-batch and between-batch coefficients of variation (CV). We also calculated the intraclass correlation coefficient (ICC) for each analyte. 51.6% of CVs were <10%, 25.8% were 10% to 15%, and 22.5% were 15% to 20% (Supplementary Table S1). We excluded from evaluation metabolite 5,6-EET given known limitations in its detection via LC/MS-MS, we further excluded two metabolites (19-HETE and 20-HETE) that were undetectable in nearly all samples. Thus, after exclusions, 31 metabolites were evaluated (17, 20, 21).

Statistical analysis

We used generalized linear models adjusted for age to calculate geometric mean concentrations of free fatty acid metabolites by case–control status and by other factors (e.g., smokers vs. nonsmokers, normal BMI versus overweight/obese BMI, and aspirin/Ibuprofen users vs. nonusers). P-values were calculated using a Wald test.

We used unconditional logistic regression models to calculate odds ratios and 95% confidence intervals (CI) for the association between prediagnostic serum levels of free fatty acid metabolites and risk of ovarian cancer. All models were adjusted for matching factors and potential confounders: parity (nulliparous/parous), duration of oral contraceptive use (never, 1–5 years, 6+ years), duration of menopausal hormone therapy use (never, 1–5 years, 6+ years), cigarette smoking status (never, former, current), and body mass index (BMI; <25, 25–29.9, 30+ kg/m2). The risk of ovarian cancer was examined across tertile categories of the metabolites based on the distribution among controls. Metabolites with 90% or more individuals with nondetectable levels were categorized into two groups (detectable vs. undetectable). A Wald test using tertile categories as a continuous variable was used to evaluate trend. For markers associated with ovarian cancer risk, we further adjusted for the inflammatory markers (CRP, TNFα, and IL8) that were positively associated with ovarian cancer risk in a previous analysis (22).

We also explored the association between free fatty acid metabolites and risk of ovarian cancer by histologic subtypes (serous vs. nonserous) and number of years from blood collection to cancer diagnosis (cancer diagnosis 2–5 years vs. >5 years from blood draw). P-values for heterogeneity were based on the Wald test for the ordinal metabolite variable from a case-only model with serous histology or the shortest time (2–5 years) between blood draw and diagnosis as the reference group.

We used fixed effect meta-analysis to calculate summary objective responses (OR) of the association of fatty acid metabolite pathways (Fig. 1) with the risk of ovarian cancer overall and by histologic subtypes.

We evaluated effect modification by BMI (normal vs. overweight/obese) and use of medication (aspirin/ibuprofen users vs. aspirin/ibuprofen nonusers) using stratified models. Likelihood ratio tests were calculated to test for interaction using the cross-product term. Because of a limited number of current smokers, we could not evaluate effect modification by smoking status, but we conducted a sensitivity analysis restricted to never/former smokers. As a secondary analysis, we evaluated the association between free fatty acid metabolites and the risk of ovarian cancer adjusting for aspirin use.

To account for multiple comparisons, we applied the false discovery rate (FDR) for the primary free fatty acid metabolites associations with the ovarian cancer. All other analyses were considered exploratory and not corrected for multiple comparisons. All tests were two-sided and statistical significance was defined using a P-value <0.05. Analyses were conducted in SAS version 9.4 (SAS Inc.).

The participants for the study were predominantly white (92.3%; Table 1). Cases used menopausal hormonal therapy for longer durations (6+ years) than controls (39.5% in cases vs. 28.8% in controls). The median number of years from blood draw to the year of cancer diagnosis was 8.2 years [interquartile range (IQR): 5.2–10.8].

Table 1.

Characteristics of ovarian cancer cases and controls in a nested case–control study in the PLCO Cancer Screening Trial

Control (N = 156)Ovarian cancer cases (N = 157)
Na (%)Na (%)
Age at randomization 
 ≤59 years 46 (29.5) 46 (29.3) 
 60–64 years 46 (29.5) 46 (29.3) 
 65–69 years 40 (25.6) 41 (26.1) 
 ≥70 years 24 (15.4) 24 (15.3) 
Race 
 Non-Hispanic white 144 (92.3) 144 (91.7) 
 Non-Hispanic black, Hispanic, Asian 12 (7.7) 13 (8.3) 
Highest education level attained 
 High school or less 49 (31.4) 45 (29.0) 
 Some post-high school training 52 (33.3) 55 (35.0) 
 College graduate 55 (35.1) 57 (36.3) 
BMI 
 <25 kg/m2 66 (42.3) 66 (42.6) 
 25–29.9 kg/m2 54 (35.0) 56 (36.1) 
 ≥30 kg/m2 36 (23.1) 33 (21.3) 
Cigarette smoking status 
 Never 101 (64.7) 84 (53.5) 
 Former 17 (10.9) 12 (7.6) 
 Current 38 (24.3) 61 (38.8) 
Age at menarche 
 <11 years 27 (17.1) 34 (21.7) 
 12–13 years 80 (51.3) 89 (56.7) 
 13+ years 49 (31.2) 34 (21.7) 
Parity 
 Nulliparous 149 (95.0) 146 (93.0) 
 Parous 8 (5.1) 11 (7.0) 
Duration of oral contraceptive use 
 Never or <1 year 77 (49.4) 86 (54.8) 
 1–5 years 50 (32.0) 48 (30.6) 
 6+ years 29 (18.6) 23 (14.6) 
Regularly uses aspirin or ibuprofen 
 Does not use aspirin or ibuprofen 66 (43.0) 55 (35.0) 
 Does not use aspirin but uses ibuprofen 21 (13.5) 25 (16.0) 
 Uses aspirin but not ibuprofen 44 (28.4) 53 (34.0) 
 Uses both aspirin and ibuprofen 24 (15.5) 24 (15.4) 
Duration of menopausal hormone therapy use 
 Never or <1 year 63 (41.0) 45 (28.7) 
 1–5 years 48 (30.7) 50 (32.0) 
 6+ years 45 (28.8) 62 (39.5) 
Control (N = 156)Ovarian cancer cases (N = 157)
Na (%)Na (%)
Age at randomization 
 ≤59 years 46 (29.5) 46 (29.3) 
 60–64 years 46 (29.5) 46 (29.3) 
 65–69 years 40 (25.6) 41 (26.1) 
 ≥70 years 24 (15.4) 24 (15.3) 
Race 
 Non-Hispanic white 144 (92.3) 144 (91.7) 
 Non-Hispanic black, Hispanic, Asian 12 (7.7) 13 (8.3) 
Highest education level attained 
 High school or less 49 (31.4) 45 (29.0) 
 Some post-high school training 52 (33.3) 55 (35.0) 
 College graduate 55 (35.1) 57 (36.3) 
BMI 
 <25 kg/m2 66 (42.3) 66 (42.6) 
 25–29.9 kg/m2 54 (35.0) 56 (36.1) 
 ≥30 kg/m2 36 (23.1) 33 (21.3) 
Cigarette smoking status 
 Never 101 (64.7) 84 (53.5) 
 Former 17 (10.9) 12 (7.6) 
 Current 38 (24.3) 61 (38.8) 
Age at menarche 
 <11 years 27 (17.1) 34 (21.7) 
 12–13 years 80 (51.3) 89 (56.7) 
 13+ years 49 (31.2) 34 (21.7) 
Parity 
 Nulliparous 149 (95.0) 146 (93.0) 
 Parous 8 (5.1) 11 (7.0) 
Duration of oral contraceptive use 
 Never or <1 year 77 (49.4) 86 (54.8) 
 1–5 years 50 (32.0) 48 (30.6) 
 6+ years 29 (18.6) 23 (14.6) 
Regularly uses aspirin or ibuprofen 
 Does not use aspirin or ibuprofen 66 (43.0) 55 (35.0) 
 Does not use aspirin but uses ibuprofen 21 (13.5) 25 (16.0) 
 Uses aspirin but not ibuprofen 44 (28.4) 53 (34.0) 
 Uses both aspirin and ibuprofen 24 (15.5) 24 (15.4) 
Duration of menopausal hormone therapy use 
 Never or <1 year 63 (41.0) 45 (28.7) 
 1–5 years 48 (30.7) 50 (32.0) 
 6+ years 45 (28.8) 62 (39.5) 

aValues may not sum to total because of missing data.

The age adjusted geometric means of the free fatty acid metabolites were similar between cases and control (Table 2). Out of 31 metabolites analyzed for an association with ovarian cancer, five (8-HETE, 12,13-DHOME, 13-HODE, 9-HODE, and 9,12,13-THOME) were positively associated with ovarian cancer risk (Table 3): 8-HETE [tertile 3 vs. 1: OR 2.53 (95% CI, 1.18–5.39), Ptrend 0.02], 12,13-DHOME [2.49 (95% CI, 1.29–4.81), 0.01], 13-HODE [2.47 (1.32–4.60), 0.005], 9-HODE [1.97 (1.06–3.68), 0.03], 9,12,13-THOME [2.25 (1.20–4.21), 0.01]. After accounting for multiple comparison, three metabolites (12,13-DHOME, 13-HODE, and 9,12,13-THOME) remained associated with ovarian cancer risk at FDR < 0.10. Increased ovarian cancer risk with the five metabolites remained after adjusting for the potential mediating effects of other inflammatory markers (e.g., CRP, TNFα, IL8; Supplementary Table S2).

Table 2.

Age-adjusted GM of arachidonic acid and linoleic acid–derived metabolites for ovarian cancer cases and controls in a nested case–control study in the PLCO Cancer Screening Trial

Control (N = 156)Ovarian cancer cases (N = 157)
Metabolites (pg/ml)GM (95% CI)GM (95% CI)P-value
Alpha-linoleic acid derived 
 17-18-Epoxy-eicosatrienoic acids (17,18-EpETE)a 827 (211–3,235) 349 (65–1,862) 0.40 
 17-18-Dihydroxyeicosatetraenoic acids (17,18-DiHETE) 1,759 (1,621–1,908) 1,850 (1,705–2,006) 0.39 
 19-20-Epoxy-docosapentaenoic acid (19,20-EpDPE) 3,044 (2,784–3,327) 3,193 (2,927–3,482) 0.45 
 19-20-Dihydroxy-docosapentaenoic acid (19,20-DiHDPA) 1,140 (1,055–1,232) 1,190 (1,102–1,286) 0.44 
Linoleic acid/COX derived 
 9-Hydroxyoctadecadienoic acid (9-HODE) 5,988 (5,423–6,612) 6,468 (5,859–7,140) 0.28 
 Trihydroxyoctadecenoic acids (9,10,13-THOME) 2,685 (2,470–2,918) 2,929 (2,696–3,183) 0.15 
Linoleic acid/LOX derived 
 13-Hydroxyoctadecadienoic acid (13-HODE) 6,018 (5,479–6,610) 6,460 (5,883–7,093) 0.29 
 Trihydroxyoctadecenoic acids (9,12,13-THOME) 1,343 (1,204–1,499) 1,442 (1,293–1,608) 0.37 
Linoleic acid/P450 derived 
 9-10-Epoxy-octadecenoic acid (9,10-EpOME) 2,016 (1,092–3,723) 1,426 (774–2,629) 0.43 
 9-10-Dihydroxyoctadecenoic acid (9,10-DHOME) 4,593 (4,158–5,075) 4,901 (4,437–5,412) 0.37 
 12–13-Epoxy-octadecenoic acid (12,13-EpOME)) 32,993 (29,346–37,092) 35,060 (31,185–39,416) 0.47 
 12-13-Dihydroxyoctadecenoic acid (12,13-DHOME) 5,041 (4,529–5,612) 5,614 (5,045–6,247) 0.16 
Arachidonic acid/COX derived 
 6-keto-Prostaglandin F (6-keto-PGF1,453 (1,300–1,625) 1,535 (1,373–1,716) 0.50 
 Prostaglandin F (PGF1,367 (1,174–1,591) 1,492 (1,284–1,735) 0.42 
 Prostaglandin E2 (PGE272.5 (59.1–89.0) 72.7 (59.2–89.2) 0.99 
 Prostaglandin D2 (PGD2)a 249 (180–343) 211 (153–291) 0.48 
 Thromboxane B2 (TXB2) 278 (191–404) 275 (189–398) 0.96 
Arachidonic acid/LOX derived    
 15-Hydroxyeicosatetraenoic acids (15-HETE) 384 (347–425) 390 (352–431) 0.83 
 12-Hydroxyeicosatetraenoic acids (12-HETE) 4,844 (3,932–5,966) 4,941 (4,014–6,082) 0.89 
 8-Hydroxyeicosatetraenoic acids (8-HETE) 5,022 (4,551–5,541) 5,325 (4,828–5,874) 0.41 
 5-Hydroxyeicosatetraenoic acids (5-HETE) 661 (615–710) 682 (635–733) 0.54 
 Leukotriene B4 (LTB-4) 200 (169–236) 255 (216–300) 0.04 
Arachidonic acid/P450 derived    
 5–6-Dihydroxyeicosatrienoic acids (5,6-DHET) 348 (322–376) 352 (326–381) 0.84 
 8-9-Epoxyeicosatrienoic acids (8,9-EET) 668 (612–729) 670 (614–731) 0.96 
 8-9-Dihydroxyeicosatrienoic acids (8,9-DHET) 226 (214–240) 230 (218–244) 0.66 
 11-12-Epoxyeicosatrienoic acids (11,12-EET) 709 (638–788) 685 (617–761) 0.65 
 11-12-Dihydroxyeicosatrienoic acids (11,12-DHET) 392 (370–414) 403 (381–426) 0.48 
 14-15-Epoxyeicosatrienoic acids (14,15-EET) 1,696 (1,511–1,905) 1,805 (1,605–2,029) 0.46 
 14-15-Dihydroxyeicosatrienoic acids (14,15-DHET) 523 (496–551) 523 (497–551) 0.98 
Arachidonic acid/nonenzymatic derived 
 11-Hydroxyeicosatetraenoic acids (11-HETE) 190 (167–215) 191 (168–216) 0.94 
 8-Iso-Prostaglandin F (8-iso-PGF)a 718 (392–1,317) 571 (302–1,080) 0.59 
Control (N = 156)Ovarian cancer cases (N = 157)
Metabolites (pg/ml)GM (95% CI)GM (95% CI)P-value
Alpha-linoleic acid derived 
 17-18-Epoxy-eicosatrienoic acids (17,18-EpETE)a 827 (211–3,235) 349 (65–1,862) 0.40 
 17-18-Dihydroxyeicosatetraenoic acids (17,18-DiHETE) 1,759 (1,621–1,908) 1,850 (1,705–2,006) 0.39 
 19-20-Epoxy-docosapentaenoic acid (19,20-EpDPE) 3,044 (2,784–3,327) 3,193 (2,927–3,482) 0.45 
 19-20-Dihydroxy-docosapentaenoic acid (19,20-DiHDPA) 1,140 (1,055–1,232) 1,190 (1,102–1,286) 0.44 
Linoleic acid/COX derived 
 9-Hydroxyoctadecadienoic acid (9-HODE) 5,988 (5,423–6,612) 6,468 (5,859–7,140) 0.28 
 Trihydroxyoctadecenoic acids (9,10,13-THOME) 2,685 (2,470–2,918) 2,929 (2,696–3,183) 0.15 
Linoleic acid/LOX derived 
 13-Hydroxyoctadecadienoic acid (13-HODE) 6,018 (5,479–6,610) 6,460 (5,883–7,093) 0.29 
 Trihydroxyoctadecenoic acids (9,12,13-THOME) 1,343 (1,204–1,499) 1,442 (1,293–1,608) 0.37 
Linoleic acid/P450 derived 
 9-10-Epoxy-octadecenoic acid (9,10-EpOME) 2,016 (1,092–3,723) 1,426 (774–2,629) 0.43 
 9-10-Dihydroxyoctadecenoic acid (9,10-DHOME) 4,593 (4,158–5,075) 4,901 (4,437–5,412) 0.37 
 12–13-Epoxy-octadecenoic acid (12,13-EpOME)) 32,993 (29,346–37,092) 35,060 (31,185–39,416) 0.47 
 12-13-Dihydroxyoctadecenoic acid (12,13-DHOME) 5,041 (4,529–5,612) 5,614 (5,045–6,247) 0.16 
Arachidonic acid/COX derived 
 6-keto-Prostaglandin F (6-keto-PGF1,453 (1,300–1,625) 1,535 (1,373–1,716) 0.50 
 Prostaglandin F (PGF1,367 (1,174–1,591) 1,492 (1,284–1,735) 0.42 
 Prostaglandin E2 (PGE272.5 (59.1–89.0) 72.7 (59.2–89.2) 0.99 
 Prostaglandin D2 (PGD2)a 249 (180–343) 211 (153–291) 0.48 
 Thromboxane B2 (TXB2) 278 (191–404) 275 (189–398) 0.96 
Arachidonic acid/LOX derived    
 15-Hydroxyeicosatetraenoic acids (15-HETE) 384 (347–425) 390 (352–431) 0.83 
 12-Hydroxyeicosatetraenoic acids (12-HETE) 4,844 (3,932–5,966) 4,941 (4,014–6,082) 0.89 
 8-Hydroxyeicosatetraenoic acids (8-HETE) 5,022 (4,551–5,541) 5,325 (4,828–5,874) 0.41 
 5-Hydroxyeicosatetraenoic acids (5-HETE) 661 (615–710) 682 (635–733) 0.54 
 Leukotriene B4 (LTB-4) 200 (169–236) 255 (216–300) 0.04 
Arachidonic acid/P450 derived    
 5–6-Dihydroxyeicosatrienoic acids (5,6-DHET) 348 (322–376) 352 (326–381) 0.84 
 8-9-Epoxyeicosatrienoic acids (8,9-EET) 668 (612–729) 670 (614–731) 0.96 
 8-9-Dihydroxyeicosatrienoic acids (8,9-DHET) 226 (214–240) 230 (218–244) 0.66 
 11-12-Epoxyeicosatrienoic acids (11,12-EET) 709 (638–788) 685 (617–761) 0.65 
 11-12-Dihydroxyeicosatrienoic acids (11,12-DHET) 392 (370–414) 403 (381–426) 0.48 
 14-15-Epoxyeicosatrienoic acids (14,15-EET) 1,696 (1,511–1,905) 1,805 (1,605–2,029) 0.46 
 14-15-Dihydroxyeicosatrienoic acids (14,15-DHET) 523 (496–551) 523 (497–551) 0.98 
Arachidonic acid/nonenzymatic derived 
 11-Hydroxyeicosatetraenoic acids (11-HETE) 190 (167–215) 191 (168–216) 0.94 
 8-Iso-Prostaglandin F (8-iso-PGF)a 718 (392–1,317) 571 (302–1,080) 0.59 

GM, geometric mean.

aPGD2, 8-iso-PGF, and 17,18-EpETE had 90% of the samples below the detection limit. The GM and CI presented are for detectable samples only.

Table 3.

Association of arachidonic acid and linoleic acid–derived metabolites and risk of overall ovarian cancer and histologic subtypes (serous and nonserous) of ovarian cancer in a nested case–control study in the PLCO Cancer Screening Trial

ControlCasesOverall casesSerous casesNonserous cases
Metabolites (pg/ml)N (%)N (%)ORa (95% CI)aN (%)OR (95% CI)N (%)OR (95% CI)P-Hetb
Alpha-linoleic acid derived 
17,18-EpETEc 
 0 152 (97.4) 154 (98.1) 1.00 (Reference) 83 (100) 1.00 (Reference) 63 (95.5) 1.00 (Reference)  
 >0 (detectable) 4 (2.6) 3 (1.9) 0.91 (0.19–4.42) — — 3 (4.5) 1.96 (0.39–9.92)  
17,18-DiHETEd 
 ≤1,356.67 52 (33.3) 41 (26.1) 1.00 (Reference) 25 (30.1) 1.00 (Reference) 16 (24.2) 1.00 (Reference)  
 >1,356.67–≤2,070 51 (32.7) 55 (35.0) 1.27 (0.70–2.30) 31 (37.4) 1.04 (0.51–2.14) 22 (33.3) 1.41 (0.64–3.11)  
 >2,070 53 (34.0) 61 (38.9) 1.48 (0.81–2.70) 27 (32.5) 0.96 (0.46–2.03) 28 (42.4) 1.89 (0.86–4.15) 0.55 
Ptrende   0.20  0.63  0.10  
19,20-EpDPE 
 ≤1,900 52 (33.3) 35 (22.3) 1.00 (Reference) 18 (21.7) 1.00 (Reference) 15 (22.7) 1.00 (Reference)  
 >1,900–≤3,448.33 50 (32.1) 66 (42.0) 1.87 (1.03–3.39) 34 (41.0) 1.67 (0.79–3.52) 31 (47.0) 2.31 (1.07–4.97)  
 >3,448.33 54 (34.6) 56 (35.7) 1.42 (0.76–2.67) 31 (37.4) 1.26 (0.58–2.76) 20 (30.3) 1.43 (0.62–3.31) 0.99 
Ptrend   0.32  0.65  0.39  
19,20-DiHDPA 
 ≤883.33 52 (33.3) 44 (28.0) 1.00 (Reference) 27 (32.5) 1.00 (Reference) 17 (25.8) 1.00 (Reference)  
 >883.33–≤1,390 51 (32.7) 56 (35.7) 1.45 (0.80–2.61) 26 (31.3) 1.04 (0.50–2.17) 27 (40.9) 1.84 (0.86–3.96)  
 >1,390 53 (34.0) 57 (36.3) 1.20 (0.65–2.19) 30 (36.1) 0.86 (0.41–1.81) 22 (33.3) 1.38 (0.62–3.10) 0.77 
Ptrend   0.60  0.47  0.42  
Linoleic acid/COX derived 
9-HODEf 
 ≤4,383.33 52 (33.3) 41 (26.1) 1.00 (Reference) 18 (21.7) 1.00 (Reference) 22 (33.3) 1.00 (Reference)  
 >4,383.33–≤7,450 51 (32.7) 48 (30.6) 1.34 (0.72–2.48) 30 (36.1) 1.93 (0.88–4.24) 15 (22.7) 0.81 (0.36–1.83)  
 >7,450 53 (34.0) 68 (43.3) 1.97 (1.06–3.68) 35 (42.2) 2.39 (1.08–5.29) 29 (43.9) 1.42 (0.65–3.08) 0.39 
Ptrend   0.03  0.06  0.36  
9,10,13-THOME 
 ≤2,153.33 52 (33.3) 35 (22.3) 1.00 (Reference) 18 (21.7) 1.00 (Reference) 15 (22.7) 1.00 (Reference)  
 >2,153.33–≤3,070.1 51 (32.7) 62 (39.5) 1.90 (1.02–3.53) 35 (42.2) 1.80 (0.83–3.88) 24 (36.4) 1.95 (0.85–4.45)  
 >3,070.1 53 (34.0) 60 (38.2) 1.83 (1.02–3.66) 30 (36.1) 1.80 (0.81–4.00) 27 (40.9) 2.00 (0.88–4.58) 0.81 
Ptrend   0.05  0.22  0.07  
Linoleic acid/LOX derived 
13-HODEf 
 ≤4,500 53 (34.0) 36 (22.9) 1.00 (Reference) 17 (20.5) 1.00 (Reference) 17 (25.8) 1.00 (Reference)  
 >4,500–≤6,800 50 (32.1) 49 (31.2) 1.71 (0.90–3.24) 28 (33.7) 2.11 (0.94–4.73) 21 (31.8) 1.55 (0.68–3.53)  
 >6,800 53 (34.0) 72 (45.9) 2.47 (1.32–4.60) 38 (45.8) 2.96 (1.34–6.56) 28 (42.4) 1.93 (0.86–4.34) 0.51 
Ptrend   0.005  0.01  0.12  
9,12,13-THOMEf 
 ≤913.33 52 (33.3) 35 (22.3) 1.00 (Reference) 21 (25.3) 1.00 (Reference) 12 (18.2) 1.00 (Reference)  
 >913.33–≤1,446.67 51 (32.7) 53 (33.8) 1.61 (0.86–3.02) 29 (34.9) 1.22 (0.57–2.62) 22 (33.3) 2.18 (0.91–5.23)  
 >1,446.67 53 (34.0) 69 (43.9) 2.25 (1.20–4.21) 33 (39.8) 1.68 (0.78–3.61) 32 (48.5) 3.00 (1.28–7.03) 0.29 
Ptrend   0.01  0.16  0.01  
Linoleic acid/P450 derived 
9,10-EpOME 
 ≤6,950 52 (33.3) 58 (36.9) 1.00 (Reference) 33 (39.8) 1.00 (Reference) 21 (31.8) 1.00 (Reference)  
 >6,950–≤19,600 51 (32.7) 44 (28.0) 0.77 (0.43–1.40) 15 (18.1) 0.48 (0.22–1.06) 27 (40.9) 1.22 (0.58–2.56)  
 >19,600 53 (34.0) 55 (35.0) 0.94 (0.53–1.65) 35 (42.2) 1.12 (0.57–2.19) 18 (27.3) 0.84 (0.39–1.81) 0.63 
Ptrend   0.83  0.70  0.56  
9,10-DHOME 
 ≤2,956.67 52 (33.3) 32 (20.4) 1.00 (Reference) 17 (20.5) 1.00 (Reference) 14 (21.2) 1.00 (Reference)  
 >2,956.67–≤5,400 51 (32.7) 68 (43.3) 2.15 (1.16–3.99) 42 (50.6) 2.17 (1.02–4.60) 21 (31.8) 1.86 (0.80–4.33)  
 >5,400 53 (34.0) 57 (36.3) 1.90 (0.98–3.67) 24 (28.9) 1.35 (0.58–3.11) 31 (47.0) 2.50 (1.06–5.90) 0.15 
Ptrend   0.07  0.60  0.04  
12,13-EpOME 
 ≤23,050 52 (33.3) 46 (29.3) 1.00 (Reference) 17 (20.5) 1.00 (Reference) 27 (40.9) 1.00 (Reference)  
 >23,050–≤48,000 50 (32.1) 48 (30.6) 1.16 (0.64–2.12) 30 (36.1) 2.23 (1.01–4.89) 16 (24.2) 0.63 (0.29–1.38)  
 >48,000 54 (34.6) 63 (40.1) 1.35 (0.75–2.44) 36 (43.4) 1.95 (0.90–4.22) 23 (34.9) 0.82 (0.39–1.73) 0.05 
Ptrend   0.32  0.13  0.67  
12,13-DHOMEf 
 ≤3,226.67 52 (33.3) 30 (19.1) 1.00 (Reference) 16 (19.3) 1.00 (Reference) 13 (19.7) 1.00 (Reference)  
 >3,226.67–≤6,233.33 51 (32.7) 59 (37.6) 2.08 (1.11–3.88) 34 (41.0) 2.11 (0.97–4.58) 22 (33.3) 1.83 (0.79–4.22)  
 >6,233.33 53 (34.0) 68 (43.3) 2.49 (1.29–4.81) 33 (39.7) 2.15 (0.95–4.87) 31 (47.0) 2.54 (1.07–6.04) 0.52 
Ptrend   0.01  0.12  0.04  
Arachidonic acid/COX derived 
6-keto-PGF 
 ≤1,138.33 52 (33.3) 48 (30.6) 1.00 (Reference) 25 (30.1) 1.00 (Reference) 20 (30.3) 1.00 (Reference)  
 >1,138.33–≤1,973.33 50 (32.1) 51 (32.5) 1.33 (0.73–2.43) 30 (36.1) 1.58 (0.75–3.31) 19 (28.8) 1.09 (0.49–2.41)  
 >1,973.33 54 (34.6) 58 (36.9) 1.42 (0.77–2.62) 28 (33.7) 1.33 (0.62–2.86) 27 (40.9) 1.47 (0.67–3.24) 0.38 
Ptrend   0.26  0.32  0.43  
PGF 
 ≤728.33 52 (33.3) 42 (26.8) 1.00 (Reference) 22 (26.5) 1.00 (Reference) 17 (25.8) 1.00 (Reference)  
 >728.33–≤2,075.00 51 (32.7) 64 (40.8) 1.48 (0.82–2.65) 32 (38.6) 1.43 (0.69–2.95) 28 (42.4) 1.61 (0.75–3.45)  
 >2,075.00 53 (34.0) 51 (32.5) 1.07 (0.58–1.96) 29 (34.9) 1.02 (0.48–2.18) 21 (31.8) 1.24 (0.56–2.75) 0.89 
Ptrend   0.86  0.91  0.60  
PGE2 
 ≤43.28 52 (33.3) 56 (35.7) 1.00 (Reference) 31 (37.4) 1.00 (Reference) 20 (30.3) 1.00 (Reference)  
 >43.28–≤124.67 51 (32.7) 46 (29.3) 0.74 (0.41–1.34) 22 (26.5) 0.56 (0.27–1.19) 22 (33.3) 1.03 (0.47–2.24)  
 >124.67 53 (34.0) 55 (35.0) 0.95 (0.53–1.72) 30 (36.1) 0.86 (0.41–1.81) 24 (36.4) 1.22 (0.56–2.64) 0.52 
Ptrend   0.87  0.66  0.63  
PGD2c 
 0 124 (79.5) 125 (79.6) 1.00 (Reference) 68 (81.9) 1.00 (Reference) 51 (77.3) 1.00 (Reference)  
 >0 (detectable) 32 (20.5) 32 (20.4) 1.01 (0.56–1.84) 15 (18.1) 0.79 (0.37–1.67) 15 (22.7) 1.35 (0.63–2.88) 0.08 
TXB2         
 ≤63.33 51 (32.7) 50 (31.8) 1.00 (Reference) 24 (28.9) 1.00 (Reference) 22 (33.3) 1.00 (Reference)  
 >63.33–≤1,350 52 (33.3) 54 (34.4) 1.02 (0.56–1.84) 31 (37.4) 1.41 (0.68–2.93) 20 (30.3) 0.70 (0.32–1.53)  
 >1350 53 (34.0) 53 (33.8) 1.08 (0.60–1.94) 28 (33.7) 1.28 (0.61–2.68) 24 (36.4) 1.04 (0.49–2.20) 0.59 
Ptrend   0.81  0.49  0.94  
Arachidonic acid/LOX derived 
15-HETE 
 ≤300.17 52 (33.3) 59 (37.6) 1.00 (Reference) 29 (34.9) 1.00 (Reference) 28 (42.4) 1.00 (Reference)  
 >300.17–≤448.33 51 (32.7) 35 (22.3) 0.62 (0.34–1.12) 20 (24.1) 0.75 (0.36–1.58) 11 (16.7) 0.43 (0.19–0.98)  
 >448.33 53 (34.0) 63 (40.1) 1.18 (0.67–2.08) 34 (41.0) 1.31 (0.65–2.63) 27 (40.9) 1.08 (0.53–2.17) 0.63 
Ptrend   0.55  0.50  0.88  
12-HETE 
 ≤2,888.33 52 (33.3) 56 (35.7) 1.00 (Reference) 28 (33.7) 1.00 (Reference) 24 (36.4) 1.00 (Reference)  
 >2,888.33–≤7,700 51 (32.7) 42 (26.8) 0.75 (0.41–1.35) 21 (25.3) 0.78 (0.37–1.64) 20 (30.3) 0.80 (0.38–1.70)  
 >7,700 53 (34.0) 59 (37.6) 1.15 (0.65–2.02) 34 (41.0) 1.39 (0.69–2.79) 22 (33.3) 0.98 (0.47–2.04) 0.37 
Ptrend   0.64  0.42  0.91  
8-HETEf 
 ≤3,581.67 52 (33.3) 43 (27.4) 1.00 (Reference) 18 (21.7) 1.00 (Reference) 24 (36.4) 1.00 (Reference)  
 >3,581.67–≤6,016.67 51 (32.7) 46 (29.3) 1.36 (0.74–2.49) 28 (33.7) 2.60 (1.18–5.73) 17 (25.8) 0.75 (0.34–1.63)  
 >6,016.67 53 (34.0) 68 (43.3) 1.82 (1.01–3.26) 37 (44.6) 2.53 (1.18–5.39) 25 (37.9) 1.15 (0.56–2.36) 0.10 
Ptrend   0.04  0.03  0.75  
5-HETE 
 ≤498.33 52 (33.3) 36 (22.9) 1.00 (Reference) 19 (22.9) 1.00 (Reference) 15 (22.7) 1.00 (Reference)  
 >498.33–≤780.00 51 (32.7) 69 (43.9) 2.25 (1.24–4.07) 35 (42.2) 2.22 (1.06–4.65) 30 (45.5) 2.45 (1.13–5.31)  
 >780.00 53 (34.0) 52 (33.1) 1.59 (0.86–2.94) 29 (34.9) 1.72 (0.80–3.69) 21 (31.8) 1.60 (0.71–3.62) 0.93 
Ptrend   0.18  0.16  0.27  
LTB-4 
 ≤78.83 52 (33.3) 40 (25.5) 1.00 (Reference) 20 (24.1) 1.00 (Reference) 16 (24.2) 1.00 (Reference)  
 >78.83–≤236.17 51 (32.7) 56 (35.7) 1.67 (0.91–3.07) 27 (32.5) 1.73 (0.80–3.76) 26 (39.4) 1.90 (0.87–4.15)  
 >236.17 53 (34.0) 61 (38.9) 1.68 (0.93–3.04) 36 (43.4) 2.23 (1.07–4.67) 24 (36.4) 1.59 (0.73–3.47) 0.75 
Ptrend   0.10  0.03  0.22  
Arachidonic acid/P450 derived 
5,6-DHET 
 ≤268.17 52 (33.3) 44 (28.0) 1.00 (Reference) 18 (21.7) 1.00 (Reference) 26 (39.4) 1.00 (Reference)  
 >268.17–≤416.50 51 (32.7) 56 (35.7) 1.33 (0.74–2.42) 36 (43.3) 2.48 (1.16–5.33) 19 (28.8) 0.73 (0.34–1.56)  
 >416.50 53 (34.0) 57 (36.3) 1.43 (0.79–2.62) 29 (34.9) 1.85 (0.84–4.08) 21 (31.8) 0.93 (0.44–1.94) 0.05 
Ptrend   0.25  0.19  0.98  
8,9-EET 
 ≤526.67 52 (33.3) 54 (34.4) 1.00 (Reference) 23 (27.7) 1.00 (Reference) 28 (42.4) 1.00 (Reference)  
 >526.67–≤820 51 (32.7) 42 (26.8) 0.77 (0.43–1.41) 24 (28.9) 1.08 (0.51–2.29) 16 (24.2) 0.63 (0.27–1.27)  
 >820 53 (34.0) 61 (38.9) 1.21 (0.67–2.17) 36 (43.4) 1.59 (0.77–3.27) 22 (33.3) 0.90 (0.43–1.87) 0.11 
Ptrend   0.52  0.22  0.90  
8,9-DHET 
 ≤186.5 52 (33.3) 42 (26.8) 1.00 (Reference) 20 (24.1) 1.00 (Reference) 20 (30.3) 1.00 (Reference)  
 >186.5–≤264.5 51 (33.3) 61 (38.9) 1.65 (0.91–3.00) 34 (41.0) 1.84 (0.86–3.91) 26 (39.4) 1.62 (0.77–3.42)  
 >264.5 53 (34.0) 54 (34.4) 1.46 (0.80–2.68) 29 (34.9) 1.57 (0.72–3.40) 20 (30.3) 1.19 (0.55–2.59) 0.32 
Ptrend   0.25  0.32  0.56  
11,12-EET 
 ≤401.67 52 (33.3) 47 (29.9) 1.00 (Reference) 25 (30.1) 1.00 (Reference) 19 (28.8) 1.00 (Reference)  
 >401.67–≤805 51 (32.7) 56 (35.7) 1.20 (0.67–2.14) 27 (32.5) 1.09 (0.53–2.25) 28 (42.4) 1.49 (0.71–3.10)  
 >805 53 (34.0) 54 (34.4) 1.13 (0.62–2.04) 31 (37.4) 1.15 (0.56–2.35) 19 (28.8) 0.98 (0.45–2.15) 0.61 
Ptrend   0.70  0.68  0.87  
11,12-DHET 
 ≤334.33 52 (33.3) 52 (33.1) 1.00 (Reference) 25 (30.1) 1.00 (Reference) 25 (37.9) 1.00 (Reference)  
 >334.33–≤441.67 51 (32.7) 52 (33.1) 1.12 (0.63–2.01) 29 (34.9) 1.29 (0.63–2.65) 22 (33.3) 0.97 (0.47–2.01)  
 >441.67 53 (34.0) 53 (33.8) 1.16 (0.65–2.10) 29 (34.9) 1.35 (0.65–2.80) 19 (28.8) 0.82 (0.39–1.76) 0.06 
Ptrend   0.61  0.55  0.74  
14,15-EET 
 ≤590 52 (33.3) 54 (34.4) 1.00 (Reference) 25 (30.1) 1.00 (Reference) 25 (37.9) 1.00 (Reference)  
 >590–≤1,765 51 (32.7) 43 (27.4) 0.74 (0.41–1.34) 23 (27.7) 0.84 (0.39–1.77) 19 (28.8) 0.78 (0.37–1.66)  
 >1765 53 (34.0) 60 (38.2) 1.01 (0.56–1.81) 35 (42.2) 1.13 (0.55–2.33) 22 (33.3) 0.85 (0.40–1.80) 0.38 
Ptrend   0.99  0.74  0.71  
14,15-DHET 
 ≤448.33 53 (34.0) 52 (33.1) 1.00 (Reference) 24 (28.9) 1.00 (Reference) 25 (37.9) 1.00 (Reference)  
 >448.33–≤578.33 50 (32.1) 51 (32.5) 1.01 (0.56–1.81) 29 (34.9) 1.03 (0.49–2.17) 21 (31.8) 0.98 (0.47–2.06)  
 >578.33 53 (34.0) 54 (34.4) 1.26 (0.70–2.27) 30 (36.1) 1.60 (0.77–3.35) 20 (30.3) 0.88 (0.41–1.88) 0.05 
Ptrend   0.45  0.26  0.87  
Arachidonic acid/nonenzymatic derived 
11-HETE 
 ≤136.50 52 (33.3) 52 (33.1) 1.00 (Reference) 27 (32.5) 1.00 (Reference) 24 (36.4) 1.00 (Reference)  
 >136.50–≤244.67 51 (32.7) 48 (30.6) 1.11 (0.62–2.00) 23 (27.7) 1.06 (0.51–2.19) 19 (28.8) 0.94 (0.42–1.99)  
 >244.67 53 (34.0) 57 (36.3) 1.23 (0.69–2.20) 33 (39.8) 1.41 (0.69–2.89) 23 (34.9) 1.10 (0.52–2.30) 0.85 
Ptrend   0.49  0.32  0.91  
8-iso-PGFc 
 0 145 (92.9) 147 (93.6) 1.00 (Reference) 76 (91.6) 1.00 (Reference) 63 (95.5) 1.00 (Reference)  
 >0 (detectable) 11 (7.1) 10 (6.4) 0.81 (0.31–2.10) 7 (8.4) 1.40 (0.47–4.15) 3 (4.6) 0.34 (0.07–1.66) 0.27 
ControlCasesOverall casesSerous casesNonserous cases
Metabolites (pg/ml)N (%)N (%)ORa (95% CI)aN (%)OR (95% CI)N (%)OR (95% CI)P-Hetb
Alpha-linoleic acid derived 
17,18-EpETEc 
 0 152 (97.4) 154 (98.1) 1.00 (Reference) 83 (100) 1.00 (Reference) 63 (95.5) 1.00 (Reference)  
 >0 (detectable) 4 (2.6) 3 (1.9) 0.91 (0.19–4.42) — — 3 (4.5) 1.96 (0.39–9.92)  
17,18-DiHETEd 
 ≤1,356.67 52 (33.3) 41 (26.1) 1.00 (Reference) 25 (30.1) 1.00 (Reference) 16 (24.2) 1.00 (Reference)  
 >1,356.67–≤2,070 51 (32.7) 55 (35.0) 1.27 (0.70–2.30) 31 (37.4) 1.04 (0.51–2.14) 22 (33.3) 1.41 (0.64–3.11)  
 >2,070 53 (34.0) 61 (38.9) 1.48 (0.81–2.70) 27 (32.5) 0.96 (0.46–2.03) 28 (42.4) 1.89 (0.86–4.15) 0.55 
Ptrende   0.20  0.63  0.10  
19,20-EpDPE 
 ≤1,900 52 (33.3) 35 (22.3) 1.00 (Reference) 18 (21.7) 1.00 (Reference) 15 (22.7) 1.00 (Reference)  
 >1,900–≤3,448.33 50 (32.1) 66 (42.0) 1.87 (1.03–3.39) 34 (41.0) 1.67 (0.79–3.52) 31 (47.0) 2.31 (1.07–4.97)  
 >3,448.33 54 (34.6) 56 (35.7) 1.42 (0.76–2.67) 31 (37.4) 1.26 (0.58–2.76) 20 (30.3) 1.43 (0.62–3.31) 0.99 
Ptrend   0.32  0.65  0.39  
19,20-DiHDPA 
 ≤883.33 52 (33.3) 44 (28.0) 1.00 (Reference) 27 (32.5) 1.00 (Reference) 17 (25.8) 1.00 (Reference)  
 >883.33–≤1,390 51 (32.7) 56 (35.7) 1.45 (0.80–2.61) 26 (31.3) 1.04 (0.50–2.17) 27 (40.9) 1.84 (0.86–3.96)  
 >1,390 53 (34.0) 57 (36.3) 1.20 (0.65–2.19) 30 (36.1) 0.86 (0.41–1.81) 22 (33.3) 1.38 (0.62–3.10) 0.77 
Ptrend   0.60  0.47  0.42  
Linoleic acid/COX derived 
9-HODEf 
 ≤4,383.33 52 (33.3) 41 (26.1) 1.00 (Reference) 18 (21.7) 1.00 (Reference) 22 (33.3) 1.00 (Reference)  
 >4,383.33–≤7,450 51 (32.7) 48 (30.6) 1.34 (0.72–2.48) 30 (36.1) 1.93 (0.88–4.24) 15 (22.7) 0.81 (0.36–1.83)  
 >7,450 53 (34.0) 68 (43.3) 1.97 (1.06–3.68) 35 (42.2) 2.39 (1.08–5.29) 29 (43.9) 1.42 (0.65–3.08) 0.39 
Ptrend   0.03  0.06  0.36  
9,10,13-THOME 
 ≤2,153.33 52 (33.3) 35 (22.3) 1.00 (Reference) 18 (21.7) 1.00 (Reference) 15 (22.7) 1.00 (Reference)  
 >2,153.33–≤3,070.1 51 (32.7) 62 (39.5) 1.90 (1.02–3.53) 35 (42.2) 1.80 (0.83–3.88) 24 (36.4) 1.95 (0.85–4.45)  
 >3,070.1 53 (34.0) 60 (38.2) 1.83 (1.02–3.66) 30 (36.1) 1.80 (0.81–4.00) 27 (40.9) 2.00 (0.88–4.58) 0.81 
Ptrend   0.05  0.22  0.07  
Linoleic acid/LOX derived 
13-HODEf 
 ≤4,500 53 (34.0) 36 (22.9) 1.00 (Reference) 17 (20.5) 1.00 (Reference) 17 (25.8) 1.00 (Reference)  
 >4,500–≤6,800 50 (32.1) 49 (31.2) 1.71 (0.90–3.24) 28 (33.7) 2.11 (0.94–4.73) 21 (31.8) 1.55 (0.68–3.53)  
 >6,800 53 (34.0) 72 (45.9) 2.47 (1.32–4.60) 38 (45.8) 2.96 (1.34–6.56) 28 (42.4) 1.93 (0.86–4.34) 0.51 
Ptrend   0.005  0.01  0.12  
9,12,13-THOMEf 
 ≤913.33 52 (33.3) 35 (22.3) 1.00 (Reference) 21 (25.3) 1.00 (Reference) 12 (18.2) 1.00 (Reference)  
 >913.33–≤1,446.67 51 (32.7) 53 (33.8) 1.61 (0.86–3.02) 29 (34.9) 1.22 (0.57–2.62) 22 (33.3) 2.18 (0.91–5.23)  
 >1,446.67 53 (34.0) 69 (43.9) 2.25 (1.20–4.21) 33 (39.8) 1.68 (0.78–3.61) 32 (48.5) 3.00 (1.28–7.03) 0.29 
Ptrend   0.01  0.16  0.01  
Linoleic acid/P450 derived 
9,10-EpOME 
 ≤6,950 52 (33.3) 58 (36.9) 1.00 (Reference) 33 (39.8) 1.00 (Reference) 21 (31.8) 1.00 (Reference)  
 >6,950–≤19,600 51 (32.7) 44 (28.0) 0.77 (0.43–1.40) 15 (18.1) 0.48 (0.22–1.06) 27 (40.9) 1.22 (0.58–2.56)  
 >19,600 53 (34.0) 55 (35.0) 0.94 (0.53–1.65) 35 (42.2) 1.12 (0.57–2.19) 18 (27.3) 0.84 (0.39–1.81) 0.63 
Ptrend   0.83  0.70  0.56  
9,10-DHOME 
 ≤2,956.67 52 (33.3) 32 (20.4) 1.00 (Reference) 17 (20.5) 1.00 (Reference) 14 (21.2) 1.00 (Reference)  
 >2,956.67–≤5,400 51 (32.7) 68 (43.3) 2.15 (1.16–3.99) 42 (50.6) 2.17 (1.02–4.60) 21 (31.8) 1.86 (0.80–4.33)  
 >5,400 53 (34.0) 57 (36.3) 1.90 (0.98–3.67) 24 (28.9) 1.35 (0.58–3.11) 31 (47.0) 2.50 (1.06–5.90) 0.15 
Ptrend   0.07  0.60  0.04  
12,13-EpOME 
 ≤23,050 52 (33.3) 46 (29.3) 1.00 (Reference) 17 (20.5) 1.00 (Reference) 27 (40.9) 1.00 (Reference)  
 >23,050–≤48,000 50 (32.1) 48 (30.6) 1.16 (0.64–2.12) 30 (36.1) 2.23 (1.01–4.89) 16 (24.2) 0.63 (0.29–1.38)  
 >48,000 54 (34.6) 63 (40.1) 1.35 (0.75–2.44) 36 (43.4) 1.95 (0.90–4.22) 23 (34.9) 0.82 (0.39–1.73) 0.05 
Ptrend   0.32  0.13  0.67  
12,13-DHOMEf 
 ≤3,226.67 52 (33.3) 30 (19.1) 1.00 (Reference) 16 (19.3) 1.00 (Reference) 13 (19.7) 1.00 (Reference)  
 >3,226.67–≤6,233.33 51 (32.7) 59 (37.6) 2.08 (1.11–3.88) 34 (41.0) 2.11 (0.97–4.58) 22 (33.3) 1.83 (0.79–4.22)  
 >6,233.33 53 (34.0) 68 (43.3) 2.49 (1.29–4.81) 33 (39.7) 2.15 (0.95–4.87) 31 (47.0) 2.54 (1.07–6.04) 0.52 
Ptrend   0.01  0.12  0.04  
Arachidonic acid/COX derived 
6-keto-PGF 
 ≤1,138.33 52 (33.3) 48 (30.6) 1.00 (Reference) 25 (30.1) 1.00 (Reference) 20 (30.3) 1.00 (Reference)  
 >1,138.33–≤1,973.33 50 (32.1) 51 (32.5) 1.33 (0.73–2.43) 30 (36.1) 1.58 (0.75–3.31) 19 (28.8) 1.09 (0.49–2.41)  
 >1,973.33 54 (34.6) 58 (36.9) 1.42 (0.77–2.62) 28 (33.7) 1.33 (0.62–2.86) 27 (40.9) 1.47 (0.67–3.24) 0.38 
Ptrend   0.26  0.32  0.43  
PGF 
 ≤728.33 52 (33.3) 42 (26.8) 1.00 (Reference) 22 (26.5) 1.00 (Reference) 17 (25.8) 1.00 (Reference)  
 >728.33–≤2,075.00 51 (32.7) 64 (40.8) 1.48 (0.82–2.65) 32 (38.6) 1.43 (0.69–2.95) 28 (42.4) 1.61 (0.75–3.45)  
 >2,075.00 53 (34.0) 51 (32.5) 1.07 (0.58–1.96) 29 (34.9) 1.02 (0.48–2.18) 21 (31.8) 1.24 (0.56–2.75) 0.89 
Ptrend   0.86  0.91  0.60  
PGE2 
 ≤43.28 52 (33.3) 56 (35.7) 1.00 (Reference) 31 (37.4) 1.00 (Reference) 20 (30.3) 1.00 (Reference)  
 >43.28–≤124.67 51 (32.7) 46 (29.3) 0.74 (0.41–1.34) 22 (26.5) 0.56 (0.27–1.19) 22 (33.3) 1.03 (0.47–2.24)  
 >124.67 53 (34.0) 55 (35.0) 0.95 (0.53–1.72) 30 (36.1) 0.86 (0.41–1.81) 24 (36.4) 1.22 (0.56–2.64) 0.52 
Ptrend   0.87  0.66  0.63  
PGD2c 
 0 124 (79.5) 125 (79.6) 1.00 (Reference) 68 (81.9) 1.00 (Reference) 51 (77.3) 1.00 (Reference)  
 >0 (detectable) 32 (20.5) 32 (20.4) 1.01 (0.56–1.84) 15 (18.1) 0.79 (0.37–1.67) 15 (22.7) 1.35 (0.63–2.88) 0.08 
TXB2         
 ≤63.33 51 (32.7) 50 (31.8) 1.00 (Reference) 24 (28.9) 1.00 (Reference) 22 (33.3) 1.00 (Reference)  
 >63.33–≤1,350 52 (33.3) 54 (34.4) 1.02 (0.56–1.84) 31 (37.4) 1.41 (0.68–2.93) 20 (30.3) 0.70 (0.32–1.53)  
 >1350 53 (34.0) 53 (33.8) 1.08 (0.60–1.94) 28 (33.7) 1.28 (0.61–2.68) 24 (36.4) 1.04 (0.49–2.20) 0.59 
Ptrend   0.81  0.49  0.94  
Arachidonic acid/LOX derived 
15-HETE 
 ≤300.17 52 (33.3) 59 (37.6) 1.00 (Reference) 29 (34.9) 1.00 (Reference) 28 (42.4) 1.00 (Reference)  
 >300.17–≤448.33 51 (32.7) 35 (22.3) 0.62 (0.34–1.12) 20 (24.1) 0.75 (0.36–1.58) 11 (16.7) 0.43 (0.19–0.98)  
 >448.33 53 (34.0) 63 (40.1) 1.18 (0.67–2.08) 34 (41.0) 1.31 (0.65–2.63) 27 (40.9) 1.08 (0.53–2.17) 0.63 
Ptrend   0.55  0.50  0.88  
12-HETE 
 ≤2,888.33 52 (33.3) 56 (35.7) 1.00 (Reference) 28 (33.7) 1.00 (Reference) 24 (36.4) 1.00 (Reference)  
 >2,888.33–≤7,700 51 (32.7) 42 (26.8) 0.75 (0.41–1.35) 21 (25.3) 0.78 (0.37–1.64) 20 (30.3) 0.80 (0.38–1.70)  
 >7,700 53 (34.0) 59 (37.6) 1.15 (0.65–2.02) 34 (41.0) 1.39 (0.69–2.79) 22 (33.3) 0.98 (0.47–2.04) 0.37 
Ptrend   0.64  0.42  0.91  
8-HETEf 
 ≤3,581.67 52 (33.3) 43 (27.4) 1.00 (Reference) 18 (21.7) 1.00 (Reference) 24 (36.4) 1.00 (Reference)  
 >3,581.67–≤6,016.67 51 (32.7) 46 (29.3) 1.36 (0.74–2.49) 28 (33.7) 2.60 (1.18–5.73) 17 (25.8) 0.75 (0.34–1.63)  
 >6,016.67 53 (34.0) 68 (43.3) 1.82 (1.01–3.26) 37 (44.6) 2.53 (1.18–5.39) 25 (37.9) 1.15 (0.56–2.36) 0.10 
Ptrend   0.04  0.03  0.75  
5-HETE 
 ≤498.33 52 (33.3) 36 (22.9) 1.00 (Reference) 19 (22.9) 1.00 (Reference) 15 (22.7) 1.00 (Reference)  
 >498.33–≤780.00 51 (32.7) 69 (43.9) 2.25 (1.24–4.07) 35 (42.2) 2.22 (1.06–4.65) 30 (45.5) 2.45 (1.13–5.31)  
 >780.00 53 (34.0) 52 (33.1) 1.59 (0.86–2.94) 29 (34.9) 1.72 (0.80–3.69) 21 (31.8) 1.60 (0.71–3.62) 0.93 
Ptrend   0.18  0.16  0.27  
LTB-4 
 ≤78.83 52 (33.3) 40 (25.5) 1.00 (Reference) 20 (24.1) 1.00 (Reference) 16 (24.2) 1.00 (Reference)  
 >78.83–≤236.17 51 (32.7) 56 (35.7) 1.67 (0.91–3.07) 27 (32.5) 1.73 (0.80–3.76) 26 (39.4) 1.90 (0.87–4.15)  
 >236.17 53 (34.0) 61 (38.9) 1.68 (0.93–3.04) 36 (43.4) 2.23 (1.07–4.67) 24 (36.4) 1.59 (0.73–3.47) 0.75 
Ptrend   0.10  0.03  0.22  
Arachidonic acid/P450 derived 
5,6-DHET 
 ≤268.17 52 (33.3) 44 (28.0) 1.00 (Reference) 18 (21.7) 1.00 (Reference) 26 (39.4) 1.00 (Reference)  
 >268.17–≤416.50 51 (32.7) 56 (35.7) 1.33 (0.74–2.42) 36 (43.3) 2.48 (1.16–5.33) 19 (28.8) 0.73 (0.34–1.56)  
 >416.50 53 (34.0) 57 (36.3) 1.43 (0.79–2.62) 29 (34.9) 1.85 (0.84–4.08) 21 (31.8) 0.93 (0.44–1.94) 0.05 
Ptrend   0.25  0.19  0.98  
8,9-EET 
 ≤526.67 52 (33.3) 54 (34.4) 1.00 (Reference) 23 (27.7) 1.00 (Reference) 28 (42.4) 1.00 (Reference)  
 >526.67–≤820 51 (32.7) 42 (26.8) 0.77 (0.43–1.41) 24 (28.9) 1.08 (0.51–2.29) 16 (24.2) 0.63 (0.27–1.27)  
 >820 53 (34.0) 61 (38.9) 1.21 (0.67–2.17) 36 (43.4) 1.59 (0.77–3.27) 22 (33.3) 0.90 (0.43–1.87) 0.11 
Ptrend   0.52  0.22  0.90  
8,9-DHET 
 ≤186.5 52 (33.3) 42 (26.8) 1.00 (Reference) 20 (24.1) 1.00 (Reference) 20 (30.3) 1.00 (Reference)  
 >186.5–≤264.5 51 (33.3) 61 (38.9) 1.65 (0.91–3.00) 34 (41.0) 1.84 (0.86–3.91) 26 (39.4) 1.62 (0.77–3.42)  
 >264.5 53 (34.0) 54 (34.4) 1.46 (0.80–2.68) 29 (34.9) 1.57 (0.72–3.40) 20 (30.3) 1.19 (0.55–2.59) 0.32 
Ptrend   0.25  0.32  0.56  
11,12-EET 
 ≤401.67 52 (33.3) 47 (29.9) 1.00 (Reference) 25 (30.1) 1.00 (Reference) 19 (28.8) 1.00 (Reference)  
 >401.67–≤805 51 (32.7) 56 (35.7) 1.20 (0.67–2.14) 27 (32.5) 1.09 (0.53–2.25) 28 (42.4) 1.49 (0.71–3.10)  
 >805 53 (34.0) 54 (34.4) 1.13 (0.62–2.04) 31 (37.4) 1.15 (0.56–2.35) 19 (28.8) 0.98 (0.45–2.15) 0.61 
Ptrend   0.70  0.68  0.87  
11,12-DHET 
 ≤334.33 52 (33.3) 52 (33.1) 1.00 (Reference) 25 (30.1) 1.00 (Reference) 25 (37.9) 1.00 (Reference)  
 >334.33–≤441.67 51 (32.7) 52 (33.1) 1.12 (0.63–2.01) 29 (34.9) 1.29 (0.63–2.65) 22 (33.3) 0.97 (0.47–2.01)  
 >441.67 53 (34.0) 53 (33.8) 1.16 (0.65–2.10) 29 (34.9) 1.35 (0.65–2.80) 19 (28.8) 0.82 (0.39–1.76) 0.06 
Ptrend   0.61  0.55  0.74  
14,15-EET 
 ≤590 52 (33.3) 54 (34.4) 1.00 (Reference) 25 (30.1) 1.00 (Reference) 25 (37.9) 1.00 (Reference)  
 >590–≤1,765 51 (32.7) 43 (27.4) 0.74 (0.41–1.34) 23 (27.7) 0.84 (0.39–1.77) 19 (28.8) 0.78 (0.37–1.66)  
 >1765 53 (34.0) 60 (38.2) 1.01 (0.56–1.81) 35 (42.2) 1.13 (0.55–2.33) 22 (33.3) 0.85 (0.40–1.80) 0.38 
Ptrend   0.99  0.74  0.71  
14,15-DHET 
 ≤448.33 53 (34.0) 52 (33.1) 1.00 (Reference) 24 (28.9) 1.00 (Reference) 25 (37.9) 1.00 (Reference)  
 >448.33–≤578.33 50 (32.1) 51 (32.5) 1.01 (0.56–1.81) 29 (34.9) 1.03 (0.49–2.17) 21 (31.8) 0.98 (0.47–2.06)  
 >578.33 53 (34.0) 54 (34.4) 1.26 (0.70–2.27) 30 (36.1) 1.60 (0.77–3.35) 20 (30.3) 0.88 (0.41–1.88) 0.05 
Ptrend   0.45  0.26  0.87  
Arachidonic acid/nonenzymatic derived 
11-HETE 
 ≤136.50 52 (33.3) 52 (33.1) 1.00 (Reference) 27 (32.5) 1.00 (Reference) 24 (36.4) 1.00 (Reference)  
 >136.50–≤244.67 51 (32.7) 48 (30.6) 1.11 (0.62–2.00) 23 (27.7) 1.06 (0.51–2.19) 19 (28.8) 0.94 (0.42–1.99)  
 >244.67 53 (34.0) 57 (36.3) 1.23 (0.69–2.20) 33 (39.8) 1.41 (0.69–2.89) 23 (34.9) 1.10 (0.52–2.30) 0.85 
Ptrend   0.49  0.32  0.91  
8-iso-PGFc 
 0 145 (92.9) 147 (93.6) 1.00 (Reference) 76 (91.6) 1.00 (Reference) 63 (95.5) 1.00 (Reference)  
 >0 (detectable) 11 (7.1) 10 (6.4) 0.81 (0.31–2.10) 7 (8.4) 1.40 (0.47–4.15) 3 (4.6) 0.34 (0.07–1.66) 0.27 

aORs and 95% CIs were estimated using unconditional logistic regression model adjusted for matching factors [age at blood collection (55–59, 60–64, 65–69, 70+ years), race (white, black, and other), study center, and time (a.m., p.m.) and date (3-month categories of blood collection)] and a priori selected risk factors (parity, duration of oral contraceptive use, duration of menopausal hormone therapy use, cigarette smoking, and BMI).

bStatistical test for heterogeneity across histologic subtypes was based on the Wald test.

cMetabolites with 90% or more individuals with nondetectable levels were categorized into detectable versus undetectable.

dTertile categories of the metabolites were based on the distribution among controls.

eP-values for trend across tertile as continuous variable were calculated using the Wald test.

fFDR q-values: 8-HETE = 0.17; 12,13-DHOME, 13-HODE, and 9,12,13-THOME = 0.06; and 9-HODE = 0.15.

In analyses by subtype (Table 3), heterogeneity was suggested for 8-HETE [serous OR (95% CI), 2.53 (1.18–5.39) vs. nonserous OR (95% CI): 1.15 (0.56–2.36), Phet 0.10] and 12,13-EpOME [1.95 (0.90–4.22) vs. 0.82 (0.39–1.73), Phet 0.05].

In pathway analyses, the linoleic acid/COX–derived [summary OR (95% CI), P-value: 0.95 (0.76,1.19), 0.004], linoleic acid/LOX–derived [1.52 (1.22–1.90), <0.001], and linoleic acid/cytochrome P450–derived [(1.21 (1.04,1.41), 0.02] pathways were associated with increased risk of ovarian cancer (Fig. 2). In analyses by subtype (Supplementary Fig. S1), linoleic acid/COX–derived [serous OR (95% CI), P-value: 1.38 (1.04–1.84), 0.03 vs. nonserous OR (95% CI), P-value: 1.31(0.99–1.73), 0.06] and linoleic acid/LOX–derived [1.49 (1.13–1.97), 0.005 vs. 1.54 (1.16–2.04), 0.003)]–pathways were associated with increased risk of both serous and nonserous ovarian cancers. Arachidonic acid/LOX–derived [1.31 (1.11–1.54), 0.001 vs. 1.11 (0.94–1.32), 0.22)] and arachidonic acid/cytochrome P450–derived [1.18 (1.02–1.36), 0.03 vs. 1.00 (0.86–1.15), 0.95)] pathways were associated with increased risk of serous ovarian cancers but not nonserous ovarian cancers. The alpha-linoleic acid–derived [0.95 (0.76–1.19), 0.66 vs. 1.27 (1.01–1.59), 0.04)] pathway was elevated for nonserous ovarian cancers but not for serous ovarian cancers.

Figure 2.

Association of arachidonic acid and linoleic acid pathways and risk of ovarian cancer overall using fixed effects meta-analysis in a nested case-control study in the PLCO Cancer Screening Trial. A,P-values for the summary odds ratio are reported. B, ORs and 95% CIs for a one tertile increase* in metabolite level were estimated using unconditional logistic regression adjusted for matching factors [age at blood collection (55–59, 60–64, 65–69, 70+ years), race (white, black, and other), study center, and time (a.m., p.m.) and date (3-month categories) of blood collection] and a priori selected risk factors (parity, duration of oral contraceptive use, duration of menopausal hormone therapy use, and cigarette smoking). *, ORs and 95% CIs for 17,18-EpETE, PGD2, and 8-iso-PGF compare detectable versus nondetectable metabolite levels.

Figure 2.

Association of arachidonic acid and linoleic acid pathways and risk of ovarian cancer overall using fixed effects meta-analysis in a nested case-control study in the PLCO Cancer Screening Trial. A,P-values for the summary odds ratio are reported. B, ORs and 95% CIs for a one tertile increase* in metabolite level were estimated using unconditional logistic regression adjusted for matching factors [age at blood collection (55–59, 60–64, 65–69, 70+ years), race (white, black, and other), study center, and time (a.m., p.m.) and date (3-month categories) of blood collection] and a priori selected risk factors (parity, duration of oral contraceptive use, duration of menopausal hormone therapy use, and cigarette smoking). *, ORs and 95% CIs for 17,18-EpETE, PGD2, and 8-iso-PGF compare detectable versus nondetectable metabolite levels.

Close modal

In sensitivity analyses, free fatty acid metabolites associations did not vary by time between blood draw and diagnosis (Supplementary Table S3). The results were not significantly modified by BMI (normal vs. overweight/obese; Supplementary Table S4).

In this prospective study exploring the association between free fatty acids and ovarian cancer, we report that five out of 31 metabolites (8-HETE, 12,13-DHOME, 13-HODE, 9-HODE, and 9,12,13-THOME) were associated with increased ovarian cancer risk. 8-HETE is produced by the metabolism of arachidonic acid and four metabolites: 12,13-DHOME, 13-HODE, 9-HODE, and 9,12,13-THOME, are derived from linoleic acid oxidation. Further supporting the individual metabolite associations, we observed increased ovarian cancer risk with the linoleic acid pathways based on meta-analysis.

Free fatty acid metabolism by the LOX pathway produces 8-HETE, 13-HODE, 9-HODE, and 9,12,13-THOME. Although the role of the LOX pathway in ovarian cancer has not been extensively evaluated, few studies support a pivotal role of the LOX pathway in ovarian cancer prognosis. Specifically, a tissue microarray study of 245 paraffin-embedded epithelial ovarian cancer samples demonstrated that strong expression of LOX receptors was indicative of worse ovarian cancer prognosis (23). An immunohistochemistry (IHC) analysis comparing expression of 12-LOX in a serous ovarian cancer cell line and normal ovarian epithelium demonstrated that expression of 12-LOX was higher in serous ovarian carcinoma compared to normal ovarian epithelium and regulated the cell growth through ERK and MAPK signaling (24). The LOX pathway metabolites (8-HETE,13-HODE, 9-HODE, and 9,12,13-THOME) are also known as PPAR-α/γ ligands, a lipid-activated transcription factor. PPAR-α promotes lipid uptake (25), whereas PPAR-γ is mostly implicated in lipid storage and adipocyte differentiation (26). Experimental data suggest that PPAR isotypes have a role in tumor suppression and/or progression, but the mechanism is unclear (22–24). Therefore, the metabolites produced by the LOX pathway may have a role in ovarian carcinogenesis via PPAR-α/γ activation.

Linoleic acid oxidation by cytochrome P450 monoxygenase produces 12,13-DHOME (isoleukotoxin diol). A study of ovarian tumors (n = 167 cases) reported overexpression of the cytochrome P450 allelic variant (CYP1B1; ref. 27). Several studies have demonstrated the role of 12,13-DHOME in suppression of the immune system, increased adipocyte differentiation, cell proliferation, and apoptosis (28, 29), and as a ligand for PPAR-γ (30). The role of 12,13-DHOME in several cellular functions might contribute to the increased risk of ovarian cancer. Furthermore, the positive association of 12,13-DHOME with risk of ovarian cancer may be related to increased production of 12,13-DHOME by CYP1B1.

To our knowledge no prior study has explored the association between pre-diagnostic levels of circulating fatty acid metabolites from pathways involving COX, LOX, and cytochrome P450 enzymes and ovarian cancer risk. The strengths of our study include a well-designed study nested within the large prospective PLCO study, with detailed information on established ovarian cancer risk factors enabling careful control for confounding and multiple comparisons. All the analytes were measured by sensitive tandem mass spectrometry. We matched cases and controls on time of day and date of blood collection to minimize any effects due to variability in storage conditions. To limit the impact of reverse causation, we excluded cases diagnosed within 2 years of blood draw. Our study also included limitations. Although we included all available cases, the number of cases included in the current study was limited. There is a possibility that the single time point measurement of these metabolites may not reflect their concentration over a longer period. To our knowledge, there are no studies on temporal variability of serum concentrations of metabolites within an individual but a systematic review looking at the change in tissue arachidonic acid after the consumption of western diet showed that decreasing the intake of linoleic acid had no effect on circulating levels of arachidonic acid (31). Thus, validation in an independent cohort is needed.

In conclusion, our data provide evidence that out of 31 fatty acid metabolites studied, five metabolites (8-HETE, 12,13-DHOME, 13-HODE, 9-HODE, and 9,12,13-THOME), generated via the LOX/cytochrome P450 linoleic acid metabolite pathway, were associated with the increased risk of ovarian cancer. In pathway analysis, ovarian cancer risk was associated with all three linoleic acid pathways (COX derived, LOX derived, and cytochrome P450 derived). As inflammation is a well-established risk factor for ovarian cancer, these precursors of inflammatory markers associated with ovarian cancer might be important to understand a potential mechanism of the etiology of ovarian cancer.

No potential conflicts of interest were disclosed.

Conception and design: P. Hartge, B. Trabert

Development of methodology: M. Hada, M.L. Edin, B. Trabert

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.L. Edin, P. Hartge, F.B. Lih, N. Wentzensen, D.C. Zeldin, B. Trabert

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Hada, M.L. Edin, N. Wentzensen, B. Trabert

Writing, review, and/or revision of the manuscript: M. Hada, M.L. Edin, P. Hartge, N. Wentzensen, D.C. Zeldin, B. Trabert

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.L. Edin, B. Trabert

Study supervision: D.C. Zeldin, B. Trabert

This work was supported by the Intramural Research Program of the National Cancer Institute. The authors would like to thank the NIH Fellows Editorial Board for comments on a draft of the authors' manuscript.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Coussens
LM
,
Werb
Z
. 
Inflammation and cancer
.
Nature
2002
;
420
:
860
7
.
2.
Crusz
SM
,
Balkwill
FR
. 
Inflammation and cancer: advances and new agents
.
Nat Rev Clin Oncol
2015
;
12
:
584
96
.
3.
Kisielewski
R
,
Tolwinska
A
,
Mazurek
A
,
Laudanski
P
. 
Inflammation and ovarian cancer—current views
.
Ginekol Pol
2013
;
84
:
293
7
.
4.
Maccio
A
,
Madeddu
C
. 
Inflammation and ovarian cancer
.
Cytokine
2012
;
58
:
133
47
.
5.
Barry
JA
,
Azizia
MM
,
Hardiman
PJ
. 
Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis
.
Hum Reprod Update
2014
;
20
:
748
58
.
6.
Trabert
B
,
Ness
RB
,
Lo-Ciganic
WH
,
Murphy
MA
,
Goode
EL
,
Poole
EM
, et al
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium
.
J Natl Cancer Inst
2014
;
106
:
djt431
.
7.
Ricciotti
E
,
FitzGerald
GA
. 
Prostaglandins and inflammation
.
Arterioscler Thromb Vasc Biol
2011
;
31
:
986
1000
.
8.
Wang
D
,
Dubois
RN
. 
Eicosanoids and cancer
.
Nat Rev Cancer
2010
;
10
:
181
93
.
9.
Hyde
CA
,
Missailidis
S
. 
Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis
.
Int Immunopharmacol
2009
;
9
:
701
15
.
10.
Di Pasquale
MG
. 
The essentials of essential fatty acids
.
J Diet Suppl
2009
;
6
:
143
61
.
11.
Calder
PC
. 
Omega-3 fatty acids and inflammatory processes
.
Nutrients
2010
;
2
:
355
74
.
12.
Simopoulos
AP
. 
Omega-3 fatty acids in inflammation and autoimmune diseases
.
J Am Coll Nutr
2002
;
21
:
495
505
.
13.
Harizi
H
,
Corcuff
JB
,
Gualde
N
. 
Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology
.
Trends Mol Med
2008
;
14
:
461
9
.
14.
Greene
ER
,
Huang
S
,
Serhan
CN
,
Panigrahy
D
. 
Regulation of inflammation in cancer by eicosanoids
.
Prostaglandins Other Lipid Mediators
2011
;
96
:
27
36
.
15.
Prorok
PC
,
Andriole
GL
,
Bresalier
RS
,
Buys
SS
,
Chia
D
,
Crawford
ED
, et al
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
.
Control Clin Trials
2000
;
21
:
273S
309S
.
16.
Hayes
RB
,
Sigurdson
A
,
Moore
L
,
Peters
U
,
Huang
WY
,
Pinsky
P
, et al
Methods for etiologic and early marker investigations in the PLCO trial
.
Mutat Res
2005
;
592
:
147
54
.
17.
Rauzi
F
,
Kirkby
NS
,
Edin
ML
,
Whiteford
J
,
Zeldin
DC
,
Mitchell
JA
, et al
Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1
.
FASEB J
2016
;
30
:
4256
66
.
18.
Edin
ML
,
Hamedani
BG
,
Gruzdev
A
,
Graves
JP
,
Lih
FB
,
Arbes
SJ
, et al
Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia
.
J Biol Chem
2018
;
293
:
3281
92
.
19.
Jerschow
E
,
Edin
ML
,
Pelletier
T
,
Abuzeid
WM
,
Akbar
NA
,
Gibber
M
, et al
Plasma 15-Hydroxyeicosatetraenoic acid predicts treatment outcomes in aspirin-exacerbated respiratory disease
.
J Allergy Clin Immunol
Practice
;
5
:
998–1007.e2
.
20.
Zha
W
,
Edin
ML
,
Vendrov
KC
,
Schuck
RN
,
Lih
FB
,
Jat
JL
, et al
Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity
.
J Lipid Res
2014
;
55
:
2124
36
.
21.
Edin
ML
,
Wang
Z
,
Bradbury
JA
,
Graves
JP
,
Lih
FB
,
DeGraff
LM
, et al
Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart
.
FASEB J
2011
;
25
:
3436
47
.
22.
Trabert
B
,
Pinto
L
,
Hartge
P
,
Kemp
T
,
Black
A
,
Sherman
ME
, et al
Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial
.
Gynecol Oncol
2014
;
135
:
297
304
.
23.
Rocconi
RP
,
Kirby
TO
,
Seitz
RS
,
Beck
R
,
Straughn
JM
 Jr
,
Alvarez
RD
, et al
Lipoxygenase pathway receptor expression in ovarian cancer
.
Reprod Sci
2008
;
15
:
321
6
.
24.
Guo
AM
,
Liu
X
,
Al-Wahab
Z
,
Maddippati
KR
,
Ali-Fehmi
R
,
Scicli
AG
, et al
Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival
.
Cancer Chemother Pharmacol
2011
;
68
:
1273
83
.
25.
Staels
B
,
Dallongeville
J
,
Auwerx
J
,
Schoonjans
K
,
Leitersdorf
E
,
Fruchart
JC
. 
Mechanism of action of fibrates on lipid and lipoprotein metabolism
.
Circulation
1998
;
98
:
2088
93
.
26.
Rangwala
SM
,
Lazar
MA
. 
Peroxisome proliferator-activated receptor gamma in diabetes and metabolism
.
Trends Pharmacol Sci
2004
;
25
:
331
6
.
27.
McFadyen
MC
,
Cruickshank
ME
,
Miller
ID
,
McLeod
HL
,
Melvin
WT
,
Haites
NE
, et al
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer
.
Br J Cancer
2001
;
85
:
242
6
.
28.
Lynes
MD
,
Leiria
LO
,
Lundh
M
,
Bartelt
A
,
Shamsi
F
,
Huang
TL
, et al
The cold-induced lipokine 12,13-diHOME promotes fatty acid transport into brown adipose tissue
.
Nat Med
2017
;
23
:
631
7
.
29.
Moran
JH
,
Weise
R
,
Schnellmann
RG
,
Freeman
JP
,
Grant
DF
. 
Cytotoxicity of linoleic acid diols to renal proximal tubular cells
.
Toxicol Appl Pharmacol
1997
;
146
:
53
9
.
30.
Medina-Gomez
G
,
Gray
S
,
Vidal-Puig
A
. 
Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor γ (PPARγ) and PPARγcoactivator-1 (PGC1)
.
Public Health Nutr
2007
;
10
:
1132
7
.
31.
Rett
BS
,
Whelan
J
. 
Increasing dietary linoleic acid does not increase tissue arachidonic acid content in adults consuming Western-type diets: a systematic review
.
Nutr Metab
(Lond) 
2011
;
8
:
36
.